Skip to main content
Fig. 1 | BMC Research Notes

Fig. 1

From: The effect of glatiramer acetate, IFNβ-1a, fingolimod, and dimethyl fumarate on the expression of T-bet, IFN-γ, and MEG3 in PBMC of RRMS patients

Fig. 1

Comparative Gene Expression Profiles in RRMS Patients: T-bet Expression Significantly Elevated in Untreated RRMS Patients (P = 0.0005) and Glatiramer acetate (GA)-Treated RRMS Patients (P = 0.03) Compared to Control Group (Ctrls). No Significant Changes Observed in IFN-γ and MEG3 Expression Levels Among Groups. All Values Represent Mean ± SEM. Comparison of T-bet, IFN-γ, and MEG3 Expression Levels in Healthy Controls, Treatment-Naïve RRMS, and GA-Treated Patients; *P < 0.05, ***P < 0.001, ns: Nonsignificant

Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us